Belatacept and Long-Term Outcomes in Kidney Transplantation

This is the authors' abstract. We don't add key points for this paper.

Seven years after transplantation, patient and graft survival and the mean eGFR were significantly higher with belatacept (both the more-intensive regimen and the less-intensive regimen) than with cyclosporine. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00256750.).